Development
Acrivon Therapeutics, Inc.
ACRV
$1.35
$0.108.00%
NASDAQ
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 17.42% | 7.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.98% | 7.83% | |||
| Operating Income | -3.98% | -7.83% | |||
| Income Before Tax | -3.97% | -9.08% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -3.97% | -9.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3.97% | -9.08% | |||
| EBIT | -3.98% | -7.83% | |||
| EBITDA | -3.98% | -7.87% | |||
| EPS Basic | -3.44% | -8.83% | |||
| Normalized Basic EPS | -3.46% | 0.05% | |||
| EPS Diluted | -3.44% | -8.83% | |||
| Normalized Diluted EPS | -3.46% | 0.05% | |||
| Average Basic Shares Outstanding | 0.50% | 0.23% | |||
| Average Diluted Shares Outstanding | 0.50% | 0.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||